Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 6/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | MAPT | P10636 | 4/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.42 |
| ▸ | BCL9 | O00512 | 1/20 | 0.41 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.41 |
| ▸ | PPARG | P37231 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | MGLL | Q99685 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3228227 | 0.91 | PDE4B (0.52) | PDE4BALDH1A1KMT2AMAPTHPGD | |
| SCHEMBL3226221 | 0.85 | PDE4B (0.51) | PDE4BALDH1A1KMT2AMAPTHPGD | |
| SCHEMBL3230208 | 0.81 | ALDH1A1 (0.47) | PDE4BALDH1A1KMT2AMAPTHPGD | |
| SCHEMBL3221880 | 0.79 | MAPT (0.45) | ALDH1A1KMT2AMAPTHPGDGAA | |
| SCHEMBL2956927 | 0.72 | PDE4B (0.61) | PDE4BPDE3A | |
| SCHEMBL13240896 | 0.71 | PDE4B (0.57) | PDE4BPDE3A | |
| SCHEMBL2970613 | 0.70 | PDE4B (0.58) | PDE4BPDE3A | |
| SCHEMBL3212468 | 0.69 | PDE4B (0.65) | PDE4BPDE3A | |
| SCHEMBL6610918 | 0.68 | MAPT (0.52) | ALDH1A1KMT2AMAPTHPGDGAA | |
| SCHEMBL2959745 | 0.68 | PDE4B (0.52) | PDE4BALDH1A1PDE3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100056791-A1 | Pyrazolopyridine carboxamide derivative and phosphodiesterase (pde) inhibitor containing the same | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2010-03-04 | — | — | US | disclosed |
| US-20100056791-A1 | Pyrazolopyridine carboxamide derivative and phosphodiesterase (pde) inhibitor containing the same | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2010-03-04 | — | — | US | disclosed |
| US-20100056791-A1 | Pyrazolopyridine carboxamide derivative and phosphodiesterase (pde) inhibitor containing the same | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2010-03-04 | — | — | US | disclosed |
| EP-2058310-A1 | PYRAZOLOPYRIDINE CARBOXAMIDE DERIVATIVE AND PHOSPHODIESTERASE (PDE) INHIBITOR COMPRISING THE DERIVATIVE | Kyorin Pharmaceutical Co., Ltd. (JP) | 2009-05-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056791-A1 | Pyrazolopyridine carboxamide derivative and phosphodiesterase (pde) inhibitor containing the same | PDE5A, PDE3A, PDE2A | PDE4B 9/4885ALDH1A1 170/4885KMT2A 1727/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.